Does RUXOLITINIB Cause Bladder transitional cell carcinoma? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Bladder transitional cell carcinoma have been filed in association with RUXOLITINIB (OPZELURA). This represents 0.0% of all adverse event reports for RUXOLITINIB.
6
Reports of Bladder transitional cell carcinoma with RUXOLITINIB
0.0%
of all RUXOLITINIB reports
1
Deaths
5
Hospitalizations
How Dangerous Is Bladder transitional cell carcinoma From RUXOLITINIB?
Of the 6 reports, 1 (16.7%) resulted in death, 5 (83.3%) required hospitalization, and 1 (16.7%) were considered life-threatening.
Is Bladder transitional cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RUXOLITINIB. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does RUXOLITINIB Cause?
Off label use (12,492)
Death (6,561)
Fatigue (5,663)
Anaemia (3,593)
Haemoglobin decreased (3,297)
Platelet count decreased (3,028)
Diarrhoea (2,531)
Asthenia (2,529)
Dizziness (2,398)
Pneumonia (2,343)
What Other Drugs Cause Bladder transitional cell carcinoma?
PIOGLITAZONE (398)
ADALIMUMAB (96)
METHOTREXATE (95)
RITUXIMAB (74)
TOCILIZUMAB (68)
INFLIXIMAB (63)
SULFASALAZINE (55)
HYDROXYCHLOROQUINE (50)
PREDNISONE (48)
LENALIDOMIDE (42)
Which RUXOLITINIB Alternatives Have Lower Bladder transitional cell carcinoma Risk?
RUXOLITINIB vs SABRIL
RUXOLITINIB vs SACCHAROMYCES CEREVISIAE
RUXOLITINIB vs SACITUZUMAB GOVITECAN
RUXOLITINIB vs SACITUZUMAB GOVITECAN-HZIY
RUXOLITINIB vs SACROSIDASE